이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

급성 심부전 치료를 위한 케톤 에스터 (KETO-AHF)

2026년 11월 4일 업데이트: University of Alberta

KETO-AHF: 급성 심부전 치료를 위한 케톤 에스터: 벤가드 무작위 대조 시험

Ketones have been suggested to have significant physiological effects in patients with heart failure. Potential mechanisms for these effects include energy provision for the failing heart and direct protective effects on other organs. Despite the strong physiological rationale, the acute effects of ketone therapy in patients with acute heart failure (AHF) is unclear. AHF is a major healthcare issue, with in-hospital mortality exceeding 10%. Therefore, we propose a vanguard randomized controlled trial to assess the effects of ketone esters in patients with AHF. Sixty patients hospitalized with AHF will be randomized to receive either 25 grams of ketone esters three times per day or a matching placebo for five days, or until death or hospital discharge. We hypothesize that ketone therapy will improve markers of systemic congestion and heart failure symptoms. Primary endpoint will be changes in NT-proBNP levels during therapy. Secondary endpoints will be KCCQ scores, and hemodynamic profile as assessed by echocardiogram. Exploratory endpoints will clinical outcomes including mortality, need for intensive care unit admission, among others.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

상세 설명

KETO-AHF (Ketone Ester for Treatment of Acute Heart Failure) is a single-site, double-blind, randomized, placebo-controlled vanguard clinical trial evaluating the feasibility, safety, and preliminary efficacy of exogenous ketone ester therapy in adults hospitalized with acute heart failure (AHF). The trial is conducted as a domain within the Heart Failure Efficacy and Research Trial (HEART) Platform master protocol framework.

Adults (≥18 years) admitted with a primary diagnosis of acute heart failure will be screened and enrolled within 48 hours of hospital admission. Eligible participants must have dyspnea and clinical evidence of congestion and meet protocol-specified laboratory and clinical criteria, including elevated NT-proBNP and adequate kidney function (eGFR >15 mL/min/1.73m²). Key exclusions include type 1 diabetes mellitus, dialysis dependence, inability to tolerate enteral therapy, and need for advanced mechanical circulatory support or inopressor therapy.

Participants will be randomized 1:1 to receive ketone ester therapy or matching placebo for up to 5 consecutive days (or until hospital discharge or death), in addition to standard-of-care acute heart failure management. Randomization will occur through a centralized web-based system using stratified randomization by sex, and both participants and study staff will remain blinded to allocation.

The investigational intervention is KetoneAid MonoEster (D-β-hydroxybutyrate bonded to R-1,3-butanediol), administered orally or enterally at 25 g three times daily (total 75 g/day). The placebo arm receives a taste- and appearance-matched placebo administered on the same schedule. Study drug administration occurs after meals with flexibility to accommodate clinical care.

The primary endpoint is change in NT-proBNP over the treatment period. Secondary outcomes include change in heart failure symptoms using the Kansas City Cardiomyopathy Questionnaire (KCCQ) Total Symptom Score and change in echocardiographic measures of cardiac function. Exploratory outcomes include glycemic control and insulin requirements, renal function, daily fluid balance adjusted for diuretic dose, and clinical outcomes through 30 days including mortality and days alive and out of hospital. The vanguard design also evaluates feasibility outcomes to inform a subsequent full-scale trial, including consent rate, representation of women, intervention adherence, and follow-up completeness.

Safety monitoring includes daily clinical assessment and laboratory monitoring (including acid-base measures), with predefined adverse events of special interest and stopping rules. An independent Data Safety Monitoring Committee (DSMC) reviews safety data at prespecified enrollment intervals.

연구 유형

중재적

등록 (추정된)

60

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Justin Ezekowitz, MD
  • 전화번호: 780-492-0712
  • 이메일: jae2@ualberta.ca

연구 연락처 백업

연구 장소

    • Alberta
      • Edmonton, Alberta, 캐나다
        • University of Alberta

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Domain-Specific Inclusion Criteria:

  1. Primary diagnosis of AHF with dyspnea on exertion or at rest, and at least two of the following: congestion on chest radiograph, rales on chest auscultation, clinically relevant edema, or an elevated jugular venous pressure [21]
  2. Admitted to the hospital for less than 48 hours
  3. Estimated glomerular filtration rate above 15 mL/min/1.73m²
  4. NT-proBNP ≥ 1000 pg/ml

Domain-Specific Exclusion Criteria:

  1. Type 1 diabetes mellitus
  2. Patients on mechanical circulatory support
  3. Patients on more than one inotrope or on inopressors
  4. Patients on dialysis
  5. Patients with non-functioning enteral tracks

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 순차적 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: KetoneAid MonoEster

Intervention Name: KetoneAid MonoEster Formulation: D-Beta Hydroxybutyrate bonded to R 1,3 Butanediol Dosing: 25 grams, three times per day Administration: Oral or enteral route Duration: 5 consecutive days, or until hospital discharge or death

Participants randomized to the intervention arm will receive KetoneAid MonoEster (D-β-hydroxybutyrate bonded to R-1,3-butanediol) administered orally or enterally at a dose of 25 g three times daily (total 75 g/day) for up to 5 consecutive days (or until discharge or death), in addition to standard of care acute heart failure management.

위약 비교기: Placebo

Matching placebo, also provided by KetoneAid, with similar administration instructions.

Participants randomized to the control arm will receive a matching placebo administered orally or enterally three times daily for up to 5 consecutive days (or until discharge or death), in addition to standard of care acute heart failure management.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change in NT-proBNP
기간: Baseline to Day 5 (or hospital discharge if earlier)

Change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) level over the 5-day intervention period comparing ketone ester versus placebo.

Baseline to Day 5 (or hospital discharge if earlier)

2차 결과 측정

결과 측정
측정값 설명
기간
Change in Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS)
기간: Baseline to Day 5 (or hospital discharge if earlier)

Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Total Symptom Score from baseline to Day 5 comparing treatment groups.

The Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS) ranges from 0 to 100, where higher scores indicate fewer heart failure symptoms and better health status, and lower scores indicate more severe symptoms and worse health status.

Baseline to Day 5 (or hospital discharge if earlier)
Change in Left Ventricular Ejection Fraction (LVEF)
기간: Baseline to Day 5 (or hospital discharge if earlier)

Change in left ventricular ejection fraction from baseline to Day 5 comparing ketone ester versus placebo.

Left ventricular ejection fraction is expressed as a percentage (%), with higher values indicating better systolic function.

Baseline to Day 5 (or hospital discharge if earlier)
Change in Mitral Inflow E/e' Ratio
기간: Baseline to Day 5 (or hospital discharge if earlier)

Change in mitral inflow E/e' ratio from baseline to Day 5 comparing ketone ester versus placebo.

E/e' ratio is a unitless measure of left ventricular filling pressure. Higher values indicate higher estimated filling pressures and worse diastolic function.

Baseline to Day 5 (or hospital discharge if earlier)
Change in Stroke Volume
기간: Baseline to Day 5 (or hospital discharge if earlier)

Change in stroke volume from baseline to Day 5 comparing ketone ester versus placebo.

Stroke volume is measured in milliliters (mL). Higher values indicate greater forward blood flow per heartbeat.

Baseline to Day 5 (or hospital discharge if earlier)
Change in Tricuspid Annular Plane Systolic Excursion (TAPSE)
기간: Baseline to Day 5 (or hospital discharge if earlier)

Change in tricuspid annular plane systolic excursion from baseline to Day 5 comparing ketone ester versus placebo.

TAPSE is measured in millimeters (mm). Higher values indicate better right ventricular systolic function.

Baseline to Day 5 (or hospital discharge if earlier)

기타 결과 측정

결과 측정
측정값 설명
기간
Change in serum creatinine
기간: Baseline to Day 5 (or discharge if earlier)

Change in renal function measured by serum creatinine over the intervention period.

Baseline to Day 5 (or discharge if earlier)
Insulin requirements
기간: Day 1 through Day 5 (or discharge if earlier)

Total insulin administered during the inpatient intervention period.

Day 1 through Day 5 (or discharge if earlier)
Glycemic control
기간: Day 1 through Day 5 (or discharge if earlier)

Daily blood glucose measurements during the intervention period.

Day 1 through Day 5 (or discharge if earlier)
Days Alive and Out of Hospital
기간: 30 days

Number of days alive and out of hospital through Day 30 after randomization.

30 days
All-cause mortality
기간: 30 days

All-cause mortality through Day 30 after randomization.

30 days
Major Adverse Kidney Events
기간: 30 days

Composite kidney outcome through Day 30, including death, new renal replacement therapy, or persistent renal dysfunction.

30 days
Daily Net Fluid Balance Adjusted for Loop Diuretic Dose
기간: Day 1 through Day 5 (or hospital discharge if earlier)

Daily net fluid balance during the inpatient intervention period (Day 1 through Day 5 or hospital discharge if earlier), adjusted for total loop diuretic dose administered.

Net fluid balance will be calculated as total fluid intake minus total fluid output and normalized to loop diuretic dose received during the same period.

Day 1 through Day 5 (or hospital discharge if earlier)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 수석 연구원: Fernando G Zampieri, MD, PhD, University of Alberta

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

유용한 링크

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2027년 1월 1일

기본 완료 (추정된)

2027년 7월 1일

연구 완료 (추정된)

2028년 3월 1일

연구 등록 날짜

최초 제출

2026년 1월 15일

QC 기준을 충족하는 최초 제출

2026년 2월 19일

처음 게시됨 (실제)

2026년 2월 25일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 9일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 4일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • KETO-01

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

예

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .